Pre-made Parsatuzumab benchmark antibody ( Whole mAb, anti-EGFL7 therapeutic antibody, Anti-NEU1/VE-STATIN/ZNEU1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-428
Pre-Made Parsatuzumab biosimilar, Whole mAb, Anti-EGFL7 Antibody: Anti-NEU1/VE-STATIN/ZNEU1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Parsatuzumab biosimilar, Whole mAb, Anti-EGFL7 Antibody: Anti-NEU1/VE-STATIN/ZNEU1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Colorectal cancer;Non-small cell lung cancer;Solid tumours|